Drug Trial Radar · NCT00545584
Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)
Last checked: Nov 19, 2026Latest source record: May 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,512
Actual
Start
Apr 1, 2007
Primary completion
Nov 19, 2009
Study completion Nov 19, 2009
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 17, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy of three strategies of lifestyle changes associated with Januvia (sitagliptin) 100 mg/day in patients with Type 2 Diabetes Mellitus (T2DM) inadequately controlled by metformin (hemoglobin A1c \[HbA1c\] 6.5-9%). A difference between the three strategies of lifestyle changes was expected.
Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
Interventions
sitagliptin phosphateDrug
sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
Comparator: DietBehavioral
Diet
Comparator: Physical ActivityBehavioral
Physical Activity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hemoglobin A1c MeasurementTime frame: Baseline and Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.